Apixaban is a potent, reversible, direct inhibitor of factor Xa. 9 In a phase 2 study, 10 the dose identified as appropriate for testing in phase 3 studies with patients undergoing major joint ...

Dr. Marcus hypothesized that dosing may be a reason for apixaban’s apparently reduced risk of GI bleeding: “As a once-a-day drug, Xarelto [rivaroxaban] exhibits a pretty steep peak level in ...

Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.

a P for interaction = 0.37.. Rates of stroke and bleeding increased with higher CHADS 2 scores, but apixiban compared with aspirin was associated with a similar risk of bleeding (P for interaction = 0 ...

Apixaban is a direct-acting oral anticoagulant that has an excellent risk–benefit profile for stroke prevention among patients with clinical atrial fibrillation. 3,5 The Apixaban for the ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status. Impaired kidney function is the principal predictor of hemorrhage in ...

The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists.